| Maintenance chemotherapy and inmunotherapy in acute lymphoblastic leukemia (author's transl) | |
| | |
MedLine Citation:
|
PMID: 6950685 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Sixty-one children with ALL were treated between 1970 an 1973 according to a scheme including: a) Remission induction with vincristine-prednisolone-daunorubicine. b) Cytoreduction therapy with 4 drugs (6-MP, MTX,Ara-C and CYCLO) combined two by two in 3 types of associations given at three months cycles. Every three months, two-week "reinductions" with vincristine and prednisolone plus one dose of i.t. MTX. c) Early therapy on CNS, according to two patterns: one group received one dose of i.t. MTX after induction, repeated every 3 months; the other group was given cranial irradiation [2,400 r] plus 5 doses of i.t. MTX. d) After three years of chemotherapy, patients were treated for two more years with BCG by scarification. Results: Complete remission was achieved in 93%. After three years of chemotherapy, 37% of the first group (not irradiated) and 55% of the second (irradiated) persisted in C.R. Twenty-five patients initiated BCG-therapy; eighteen of these (72%) persisted, after 2 years, in C.R.; then all treatment was suppressed. Initial relapses in the 5 years period were hematological in 13, CNS in 13, both hematological and CNS in 2, and testicular in 3. Mortality of patients in C.R. was 4 (7.7%). Survival rates were 33% after 5 years for the non-irradiated group and 50% in the irradiated one. At present, 30% of all evaluable patients who attained remission continue in C.R. after an average time of 102 months-40% in the irradiated group and 20% in the not irradiated-. This difference, statistically significant, is due to the number of CNS relapses: 13 of 30 (43%) in the first group and 3 of 22 (13.1%) in the second. The 24% relapses occurring during immunotherapy do not permit to assess the efficacy of this form of therapy. |
| | |
Authors:
|
J J Ortega; G Javier |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; English Abstract; Journal Article |
Journal Detail:
|
Title: Anales españoles de pediatría Volume: 15 ISSN: 0302-4342 ISO Abbreviation: An. Esp. Pediatr. Publication Date: 1981 Oct |
Date Detail:
|
Created Date: 1982-05-21 Completed Date: 1982-05-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0420463 Medline TA: An Esp Pediatr Country: SPAIN |
Other Details:
|
Languages: spa Pagination: 357-64 Citation Subset: IM |
Vernacular Title:
|
Terapéutica de mantenimiento con quimioterapia seguida de inmunoterapia en L.A.L. infantiles (protocolo C-70). |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage* BCG Vaccine / adverse effects, therapeutic use Child Child, Preschool Drug Therapy, Combination Female Humans Infant Leukemia, Lymphoid / mortality, therapy* Male Prognosis Random Allocation |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/BCG Vaccine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Blastomycosis in immunosuppressed patients.
Next Document: The major histocompatibility complex.